This is a mobile optimized page that loads fast, if you want to load the real page, click this text.

GSS - Genetic Signatures

Jump to new

System

Joined
27 June 2010
Posts
4,335
Reactions
368
Genetic Signatures is a specialist molecular diagnostics (MDx) company focused on the development and commercialisation of its proprietary platform technology, 3Base™.

Genetic Signatures has developed and commercialised a suite of real time PCR based products which are now being used by major hospitals in Australia for the routine detection of infectious diseases. The Company's proprietary MDx technology provides high-volume hospitals and pathology laboratories with the ability to screen for a wide array of infectious pathogens with a high degree of specificity in a rapid throughput (time to result) environment.

http://geneticsignatures.com
 
Entered for the October stock tipping. From a charting perspective, it seems to be range-bound and could possibly break to the upside, hence the pick.

 
holding up in these turbulent times; mentioned by TEK and in The Australian as a beneficiary, with the patented proprietary platform technology, 3Base™ able to diagnose coronavirus (though validation needed to distinguish between Covid-19 and SARS, for example).

But still in the development, regulatory approval and commercialisation stages. Holding lotsa cash, $40mill, raised from instos and shareholder base in November.


 
Yeah good call I bought into this off the Ann a couple of days ago. I like how it’s cashed up and there should be plenty of orders for the testing kits this month. My average ended up being about $1.90 but still pretty happy. Hopefully TDL can come out of its suspension and put up some comparisons of respective testing kits.
 
GSS has received notice from the Therapeutic Goods Administration that its EasyScreenTM SARS-CoV-2 Detection Kit has been approved to be listed on the ARTG in Australia. Local registration follows formal European authorisation which was announced on 4 April 2020.


I wonder if this is going to fly? Will it prove indispensible, or just one of many pathways?
Swervin Mervin said:
Hopefully TDL can come out of its suspension and put up some comparisons of respective testing kits.
Click to expand...
- no movement at that station, 5 weeks into suspension (struggling to get Chinese approval?)


GSS is nudging its recent $2 highs again
 
Hoping for a bit of a pullback from the first run-up, but the Investor Presentation of 28 May just gave it a further leg up.

Infectious diseases continue to dominate global health threats: major contributor to global mortality and morbidity dominating WHO’s 2019 list of health threats and amplified by recent coronavirus outbreak.

Trusted and proven technology with third party validation: Genetic Signatures have achieved 100% customer retention since 2016 and the accuracy of the technology has been clinically validated.

COVID-19 pandemic creating new opportunities for global expansion: increasing international recognition through the EasyScreenTM SARS-CoV-2 launch creates new avenues to expand customer base.

On track to achieve multiple commercial milestones in 2020: international interest bolstered by the SARS-CoV-2 product release creates a platform for new contract wins for broader EasyScreenTM products.

Attractive and scalable revenue model: highly scalable business model with favourable unit economics expected to underpin growth through FY20 and beyond.

Competitive advantage underpinned by novel 3baseTM technology:resistant to genetic mutations in the micro-organisms, and implemented in a simplified workflow processes, increasing throughput capacity, reducing time to results and creating cost saving benefits

 
From 21 Dec:
Half Year Sales
Genetic Signatures has had a strong year to date and expects sales of at least $21m for the half year. First quarter sales were a company record $12.4m supported by a surge in SARS-CoV-2 testing in Australia. The recent emergence of the Omicron variant has seen testing volumes increase dramatically in the past two weeks. This increased testing will likely continue into 2022.

SARS-CoV-2 Update
At the beginning of December a new, highly transmissible SARS-CoV-2 Omicron variant was identified and classified as a variant of concern by the WHO. Genetic Signatures determined via in silico analysis that the current EasyScreen™ SARS-CoV-2 Detection Kit was able to detect all known variants, including the Omicron variant and has advised its customers.
Since then, a new detection kit has been developed, the EasyScreen™ SARS-CoV-2 Variant Detection Kit. This was designed in collaboration with customers to differentiate the Omicron and Delta variants prior to sequencing. Performance of the new kit has been confirmed in-house against more than 300 clinical patient samples. The new kit is being offered initially as Research Use Only and can identify mutations specific to Delta or Omicron in SARS-CoV-2 positive samples. The test can be used either in parallel with, or as a reflex test to the primary screen.
Customers have already expressed interest in using this test as an adjunct to Genetic Signatures’ standard test that will allow for the prioritisation of suspected Omicron positive patient samples for genomic sequencing and epidemiological studies.

And today (10 Jan) :
GSS advises that the Therapeutic Goods Administration (TGA) recently registered a saliva-based protocol for collecting and testing patient samples for SARS-CoV-2 using the Company’s 3base® EasyScreen™ SARS-CoV-2 Detection Kit. A recent study from scientists in South Africa demonstrated that saliva swabs could be more effective than mid-turbinate nasal swabs in detecting the Omicron variant in PCR based tests, due to a higher viral RNA load in saliva than in nasal samples. This is different to other variants such as Delta that are more reliably detected from a nasal swab.
now $1.80. Was $1.30 prior to the Dec Announcement
 
market cap $70 million
raised capital recently
R&D tax rebate of $6.9M


.

.
...noticed Mirrabooka took a position in the last 6 months
 
Good afternoon

15 quarters of coin ($41.3 million cash balance) in the bank as at 30 September 2024.
The loss for the consolidated entity after providing for income tax amounted to $17,862,000 (30 June 2023: $14,052,000).

In Q1 FY2025, the Company recorded sales of $4.7 million (unaudited), which was an increase of 294% on the prior corresponding period (pcp). Sales during the quarter were positively impacted by resumption of sales of the EasyScreen™ Respiratory Pathogen Detection Kit after the Therapeutic Goods Administration (TGA) authorised the sale of the updated version in Australia.

Weekly Chart


Not holding

kind regards
rcw1
 
AGM

Commercial sales in the US imminent
✓ Customer experience sites well-advanced in internal review process with several at the final contract stage
✓ Established a strong sales pipeline with >60 customer sites at various stages of
the evaluation and sales process
✓ Engaged with all major commercial reference labs in the US who have expressed interest – 50% target market but also requires longer sales cycle
✓ Continue to build brand awareness for technology and products with both the EasyScreenTM Gastrointestinal Parasite Detection Kit and 3base® platform through booth-presence at key conferences in the United States and globally
✓ Multiple publishing opportunities with Key Opinion Leaders from Johns Hopkins, Wadsworth, South Dakota and University of Kentucky

For the year ahead
Our Customers
• Several customer experience sites at final contract stage
• A strong sales pipeline, incl major US reference labs
• New signed contracts in UK
• Evaluations underway in UK and Germany
• Implementing sales excellence methodologies to further strengthen

Our Products
• Evolution of EasyScreen detection kits
• Technology and workflow improvements
• Development of next generation instrument prototype

 
Quarterly Activities Report and Appendix 4C​
HIGHLIGHTS
• Quarterly sales of $3.8 million with higher respiratory testing rates in Australia, representing, an increase of 190% on the prior corresponding period;
• Receipt of $5.1 million from the Australian Research & Development Tax Incentive;
• US sales cycles are longer than anticipated although they continue to advance positively with prospective customers at various stages;
• Research and Development focused on further optimising the performance, automation and workflow of the 3base® technology platform and overall testing solution;
• Strong balance sheet with $40.8 million cash balance at end of the quarter.

 
and now $0.55 ... down 10 percent
.
The Appendix 3Y for Dr Gunn includes the issue of 500,000 options, approved by shareholders at the Company’s 2024 Annual General Meeting on 20 November 2024, and notified in the Appendix 3G –Notification regarding unquoted securities released to the market on 9 December 2024.

In relation to the late lodgement of the attached Appendix 3Y, we advise as follows:
1. The Appendix 3Y is being lodged late due to an administrative oversight. As soon as the oversight was identified, the document was prepared and promptly lodged with the ASX.
2. The Company is satisfied that it has the necessary reporting and notification practices in place to ensure compliance with its disclosure requirements under ASX Listing Rules 3.19A and 3.19B.
3. The Company considers that the late lodgement is an isolated incident and believes that its current practices are adequate to ensure compliance with the ASX Listing Rules..
.
yes, that'll do it
 
@mullokintyre

A singularly unsuccessful tip for the CY2025 competition. There have been the usual announcements since Jan, and the SP is falling away all the while. What will the next Quarterly update bring?

 
Last edited:
a steady retracement as per my cunning plan to stand out in the CY2025 tipping comp @mullokintyre

has been as low as $0.36 this year

.
not much news in April
 
This month's post for the yearly Comp @mullokintyre

Sideways or even down, a low for the CY, no announcements of note
 
You must log in or register to reply here.
Menu
Log in
Register
Cookies are required to use this site. You must accept them to continue using the site. Learn more...